Mipomersen: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 58 patients with severe hypercholesterolemia showed that once-weekly subcutaneous injections of 200 mg mipomersen for 26 weeks significantly reduced APOB by 36% vs. an 11% increase for placebo (p<0.001). Mipomersen also significantly reduced total cholesterol and non-HDL cholesterol by 28% and 34%, respectively, vs. 11% and 14% increases for placebo (p<0.001 for both). Data were presented at the American College of Cardiology meeting in New Orleans. The partners previously reported that mipomersen met the primary endpoint of significantly reducing LDL-C from baseline to week 28 vs. placebo (see BioCentury, Aug. 9, 2010). ...